(202) 599-8435

Partner Headlines

Recent Survey Shows Americans with Chronic Pain Experience Barriers To Accessing Pain Medications

For 100 million Americans living with pain, access to pain medication is vital to functioning in their everyday lives. Many patients face both barriers with finding treating physicians and...
Posted on Sep 20, 2016
, By

Achieving a Balance in Opioid Prescribing is Vitally Important

Physicians must find the delicate balance needed to address abusers procuring pharmaceuticals from multiple prescribers while simultaneously safeguarding their legitimate chronically and...
Posted on Jun 16, 2016
, By

ACPA’s Pain Log Application Helps Patients Effectively Communicate with Their Health Care Providers

The American Chronic Pain Association (ACPA) has unveiled a new application to help patients communicate more productively with their health care providers about their pain. The Pain Log...
Posted on Apr 01, 2016
, By

Tim Hermes from Collegium Discusses the Fallacy of Traditional Fail-First Policies Applied to Abuse-Deterrent Opioids

Abuse-deterrent opioids (ADOs) are important tools in the fight against opioid abuse. ADOs mitigate certain types of opioid abuse by making manipulation of the tablet or capsule more difficult by...
Posted on Mar 25, 2016
, By

National Family Partnership Mourns Loss of Nancy Reagan & Remembers Her Work To Reduce Substance Use

On March 6, 2016, former first lady, Nancy Reagan passed away. Serving as the National Family Partnership’s (NFP) past honorary chair, Ms. Reagan was a catalyst for educational drug prevention...
Posted on Mar 10, 2016
, By

Lynn Webster Discusses Need for Prescriber Guidelines that Pay Attention to the Needs of Patients with Pain

A recent Washington Post article discusses the balancing act that practitioners specializing in pain management face: adequately treating patients’ pain while preventing harm to patients by...
Posted on Feb 01, 2016
, By

FDA Fast Tracks Braeburn’s Long-Acting Buprenorphine Injection for Opioid Dependence

The U.S. Food and Drug Administration (FDA) granted fast track designation for Braeburn Pharmaceuticals’ buprenorphine subcutaneous injection product to treat opioid use disorders. The...
Posted on Nov 16, 2015
, By